Search

Your search keyword '"Hidaka, Tomonori"' showing total 99 results

Search Constraints

Start Over You searched for: Author "Hidaka, Tomonori" Remove constraint Author: "Hidaka, Tomonori"
99 results on '"Hidaka, Tomonori"'

Search Results

51. TET2 Mutation Associated with Organ Infiltrations in ATLL

53. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1

54. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice

55. Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations

56. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma

57. TET2 mutation in diffuse large B-cell lymphoma

58. Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice

59. Mogamulizumab for ATLL in Clinical Practice

60. Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma

61. Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma

62. Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma

63. A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.

64. Integrated molecular analysis of adult T cell leukemia/lymphoma

65. Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms

66. TET2 Mutation in Adult T-Cell Leukemia/Lymphoma

67. Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy

70. Prognostic Factor, Including Relative Dose Intensity, For Adult T-Cell Leukemia/Lymphoma In Clinical Practice

72. CD3 and EBER double positive cells in bone marrow are a diagnostic aid for EBV-positive T-cell lymphoproliferative disorders of childhood

74. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture

75. Clinical significance of CADM1/TSLC1/IgSF4 expression in Adult-T cell leukemia/lymphoma (ATLL): identification of various types of ATLL cells

76. NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

78. Downregulation of CDKN1A in Adult T-Cell Leukemia/Lymphoma despite Overexpression of CDKN1A in Human T-Lymphotropic Virus 1-Infected Cell Lines

80. Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.

82. Overwhelming Postsplenectomy Infection 22 Years After Splenectomy

87. CARD11Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ

88. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

89. Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis

90. Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis

91. TET2Mutation Associated with Organ Infiltrations in ATLL

92. Haploinsufficiency of CALRConfers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the CalrMutation

93. Predictors of impaired antibody response after SARS-CoV-2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study.

94. Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma.

95. [Myeloproliferative neoplasms: revisions in the 2016 WHO criteria].

96. Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2 V617F-induced Murine Myeloproliferative Neoplasm.

97. [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].

98. [Antiphospholipid syndrome with autoimmune hemolytic anemia which mimics thrombotic thrombocytopenic purpura].

99. [ATL (lymphoma type) presented with a mass formation in the heart].

Catalog

Books, media, physical & digital resources